A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)

被引：0

作者：

Weinblatt, Michael E. ^{[1
]}

Baranauskaite, Asta ^{[2
]}

Niebrzydowski, Jaroslaw ^{[3
]}

Dokoupilova, Eva ^{[4
]}

Zielinska, Agnieszka ^{[5
]}

Sitek-Ziolkowska, Karina ^{[6
]}

Jaworski, Janusz ^{[7
]}

Racewicz, Artur ^{[8
]}

Pileckyte, Margarita ^{[2
]}

Jedrychowicz-Rosiak, Krystyna ^{[9
]}

Zhdan, Vyacheslav ^{[10
]}

Cheong, Soo Yeon ^{[11
]}

Ghil, Jeehoon ^{[11
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Lithuanian Univ Hlth Sci, Kaunas, Lithuania

[3] Med Pro Familia, Gdynia, Poland

[4] Med Plus Sro, Uherske Hradiste, Czech Republic

[5] Med Pro Familia, Warsaw, Poland

[6] Med Pro Familia, Katowice, Poland

[7] Reumatika Ctr Reumatol, Warsaw, Poland

[8] Zdrowie Osteomed Sc, Bialystok, Poland

[9] Mazowieckie Ctr Badan Klin, Grodzisk Mazowiecki, Poland

[10] MV Sklifosovskyi Poltava Reg Clin Hosp, Poltava, Ukraine

[11] Samsung Bioepis Co Ltd, Inchon, South Korea

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[31] A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRA®) to the reference product (Humira®) in patients with active rheumatoid arthritis
Jamshidi, Ahmadreza
Gharibdoost, Farhad
Vojdanian, Mahdi
Soroosh, Soosan G.
Soroush, Mohsen
Ahmadzadeh, Arman
Nazarinia, Mohammad Ali
Mousavi, Mohammad
Karimzadeh, Hadi
Shakibi, Mohammad Reza
Rezaieyazdi, Zahra
Sahebari, Maryam
Hajiabbasi, Asghar
Ebrahimi, Ali Asghar
Mahjourian, Najmeh
Rashti, Amin Mohammadinejad
ARTHRITIS RESEARCH & THERAPY, 2017, 19
[32] Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52-92 data from a randomized, double-blind, phase 3 trial
Fleischmann, Roy M.
Alvarez, Daniel F.
Bock, Amy E.
Cronenberger, Carol
Vranic, Ivana
Zhang, Wuyan
Alten, Rieke
ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
[33] Efficacy, safety and immunogenicity of GP2015, an etanercept biosimilar, compared with the reference etanercept in patients with moderate-to-severe rheumatoid arthritis: 24-week results from the comparative phase III, randomised, double-blind EQUIRA study
Matucci-Cerinic, Marco
Allanore, Yannick
Kavanaugh, Arthur
Buch, Maya H.
Schulze-Koops, Hendrik
Kucharz, Eugeniusz J.
Woehling, Heike
Babic, Goran
Poetzl, Johann
Davis, Adanna
Schwebig, Arnd
RMD OPEN, 2018, 4 (02):
[34] A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Efficacy, Safety and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Wiland, Piotr
Jeka, Slawomir
Dokoupilova, Eva
Miranda Limon, Juan Manuel
Jauch-Lembach, Julia
Thakur, Anjali
Haliduola, Halimuniyazi
Gaylis, Norman B.
ARTHRITIS & RHEUMATOLOGY, 2018, 70
[35] Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
Lin Cai
Linfeng Li
Hao Cheng
Yangfeng Ding
Zhenshu Biao
Shifa Zhang
Songmei Geng
Quanzhong Liu
Hong Fang
Zhiqi Song
Yan Lu
Shanshan Li
Qing Guo
Juan Tao
Li He
Jun Gu
Qinping Yang
Xiuping Han
Xinghua Gao
Danqi Deng
Shenqiu Li
Qingyu Wang
Jun Zhu
Jianzhong Zhang
Advances in Therapy, 2022, 39 : 583 - 597
[36] Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study
Cai, Lin
Li, Linfeng
Cheng, Hao
Ding, Yangfeng
Biao, Zhenshu
Zhang, Shifa
Geng, Songmei
Liu, Quanzhong
Fang, Hong
Song, Zhiqi
Lu, Yan
Li, Shanshan
Guo, Qing
Tao, Juan
He, Li
Gu, Jun
Yang, Qinping
Han, Xiuping
Gao, Xinghua
Deng, Danqi
Li, Shenqiu
Wang, Qingyu
Zhu, Jun
Zhang, Jianzhong
ADVANCES IN THERAPY, 2022, 39 (01) : 583 - 597
[37] A Randomized, Double-Blind Study Comparing Pharmacokinetics and Pharmacodynamics of Proposed Biosimilar ABP 798 With Rituximab Reference Product in Subjects With Moderate to Severe Rheumatoid Arthritis
Burmester, Gerd
Chien, David
Chow, Vincent
Gessner, Melissa
Pan, Jean
Cohen, Stanley
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 1003 - 1014
[38] FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
Genovese, Mark C.
Glover, Josephine
Greenwald, Maria
Porawska, Wieslawa
El Khouri, Elias Chalouhi
Dokoupilova, Eva
Vargas, Juan Ignacio
Stanislavchuk, Mykola
Kellner, Herbert
Baranova, Elena
Matsunaga, Nobuhito
Alten, Rieke
ARTHRITIS RESEARCH & THERAPY, 2019, 21 (01)
[39] FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension
Mark C. Genovese
Josephine Glover
Maria Greenwald
Wieslawa Porawska
Elias Chalouhi El Khouri
Eva Dokoupilova
Juan Ignacio Vargas
Mykola Stanislavchuk
Herbert Kellner
Elena Baranova
Nobuhito Matsunaga
Rieke Alten
Arthritis Research & Therapy, 21
[40] A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis
Kay, Jonathan
Jaworski, Janusz
Wojciechowski, Rafal
Wiland, Piotr
Dudek, Anna
Krogulec, Marek
Jeka, Slawomir
Zielinska, Agnieszka
Trefler, Jakub
Bartnicka-Maslowska, Katarzyna
Krajewska-Wlodarczyk, Magdalena
Klimiuk, Piotr
Furst, Daniel
Lee, SangJoon
Bae, Yunju
Yang, Goeun
Yoo, JaeKyoung
Lee, HyunJin
Keystone, Edward C.
ARTHRITIS & RHEUMATOLOGY, 2020, 72

← 1 2 3 4 5 →